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IMPLEMENTATION AND OPERATIONAL RESEARCH: EPIDEMIOLOGY AND PREVENTION
CD4 Count Monitoring Frequency and Risk of CD4 Count
Dropping Below 200 Cells Per Cubic Millimeter Among
Stable HIV-Infected Patients in New York City, 2007–2013
Julie E. Myers, MD, MPH,*† Qiang Xia, MD, MPH,* Lucia V. Torian, PhD,* Mary Irvine, DrPH, MPH,*
Graham Harriman, MA,* Kent A. Sepkowitz, MD,‡ and Colin W. Shepard, MD*
Introduction: The evidence has begun to mount for diminishing
the frequency of CD4 count testing. To determine whether these
observations were applicable to an urban US population, we used
New York City (NYC) surveillance data to explore CD4 testing
among stable patients in NYC, 2007–2013.
Methods: We constructed a population-based retrospective open
cohort analysis of NYC HIV surveillance data. HIV+ patients aged
$13 years with stable viral suppression ($1 viral load the previous
year; all ,400 copies per milliliter) and immune status ($1 CD4 the
previous year; all$200 cells per cubic millimeter) entered the cohort
the following year beginning January 1, 2007. Each subsequent year,
eligible patients not previously included entered the cohort on
January 1. Outcomes were annual frequency of CD4 monitoring and
probability of maintaining CD4 $200 cells per cubic millimeter. A
multivariable Cox model identified factors associated with main-
taining CD4 $200 cells per cubic millimeter.
Results: During 1.9 years of observation (median), 62,039 patients
entered the cohort. The mean annual number of CD4 measurements
among stable patients was 2.8 and varied little by year or
characteristic. Two years after entering, 93.4% and 97.8% of those
with initial CD4 350–499 and CD4 $500 cells per cubic millimeter,
respectively, maintained CD4 $200 cells per cubic millimeter.
Compared to those with initial CD4 $500 cells per cubic millimeter,
those with CD4 200–349 cells per cubic millimeter and CD4 350–
499 cells per cubic millimeter were more likely to have a CD4 ,200
cells per cubic millimeter, controlling for sex, race, age, HIV risk
group, and diagnosis year.
Conclusions: In a population-based US cohort with well-
controlled HIV, the probability of maintaining CD4 $200 cells
per cubic millimeter for $2 years was .90% among those with
initial CD4 $350 cells per cubic millimeter, suggesting that limited
CD4 monitoring in these patients is appropriate.
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INTRODUCTION
Although there have been great advances in the
treatment of persons living with HIV since the beginning of
the epidemic, there have been fewer innovations in the routine
laboratory monitoring of HIV-infected patients. One of the
first laboratory tests that emerged for such patients, the CD4
cell count, is still used by clinicians to determine a patient’s
level of immunosuppression at diagnosis and to determine the
need for either initiation or discontinuation of prophylaxis for
certain opportunistic infections (OIs). However, once a patient
achieves stable virologic suppression [one of the goals of
antiretroviral therapy (ART)], and is no longer near a thresh-
old for OI prophylaxis, the benefit of CD4 cell count testing
has been called into question.1
This lack of clarity about the utility of ongoing CD4
cell count testing in certain situations was, until very recently,
reflected in disparate recommendations about the frequency
of such monitoring in clinical guidelines and protocols, both
national and local.2–4 In addition, certain systems for perfor-
mance measurement, such as HIVQUAL (a national contin-
uous quality control project), required CD4 monitoring every
6 months.5 This confusion has left clinicians in a situation
where they might have felt compelled to order CD4 tests at
least biannually to match the guidelines and/or quality
management protocols, despite the fact that such testing
would have often been of limited clinical utility, and,
therefore, might represent an overutilization of health care
resources.6 Expectations by patients for such testing with each
blood draw, based on years of having understood this to be
the single most important indicator of their HIV-related
health, may also have fueled such testing.
However, over the past 2 years, the evidence has begun
to mount for both (1) using virologic monitoring as the
preferred monitoring approach and (2) diminishing the
frequency of CD4 cell count testing. In terms of the former,
a recent systematic review7 included 2 studies (1 a randomized
clinical trial; 1 an observational study) that found a longer
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duration of viremia and longer time to switching to a second-
line regimen with clinical and immunologic monitoring alone
versus clinical and immunologic monitoring plus virologic
monitoring8,9; a mortality advantage in patients with virologic
monitoring was found in the observational study as well.8
Ultimately, both studies provided the basis for 2013 World
Health Organization guidelines that strongly recommended
the use of virologic monitoring to both diagnose and confirm
ART failure in all settings, including low-resource ones10; it
was specified that clinical and immunologic monitoring
should only diagnose treatment failure in the absence of the
availability of virologic monitoring.
In terms of the rationale for the diminished frequency
of CD4 cell count testing, at least 5 recent analyses suggest
that less frequent testing among certain HIV-infected
patients might be appropriate. Using electronic record data
from 1 Veteran’s Administration HIV clinic paired with
selective chart review, Gale et al11 determined that less
frequent CD4 count testing might be appropriate, based on
the fact that, among other findings, no clinically stable
patient in their analysis with a CD4 count $300 cells per
cubic millimeter had a CD4 dip (defined as a CD4 count
,200 cells per cubic millimeter) after 2 years of continuous
viral suppression. Similarly, using data from the ARTEMIS
clinical trial, Girard et al12 found that CD4 testing was
beneficial in the first 48 weeks of ART, but those patients
who achieved virologic suppression and had CD4 counts
equal or above 200 cells per cubic millimeter had little
clinical benefit beyond 48 weeks. In addition, 1 recent
retrospective chart review from Australia demonstrated that
none of the 162 decisions to modify or discontinue ART
over a 30-month period were based on a CD4 count.13
However, all of these studies include a small sample that
may not be representative of the entire population for
various reasons. A more recent study also found uncertain
utility of CD4 monitoring among a large program-based
cohort of South African patients in a very poor township,14
but these patients may not be representative of patients
outside of the resource-limited setting. Even more recently,
in an observational cohort in the Asia–Pacific region, there
was no significant difference in time to a confirmed CD4
,200 cells per cubic millimeter between biannual and
annual CD4 measurement cohorts.15 This mounting evi-
dence was reflected in 2014 US guidelines proposing that
CD4 count monitoring for stable virologically suppressed
patients with CD4 counts consistently between 300 and 500
be conducted annually; the guidelines considered CD4
count monitoring for stable virologically suppressed pa-
tients with CD4 counts consistently .500 cells per cubic
millimeter to be optional.2
To determine whether these observations were applica-
ble to a large urban US population receiving care under usual
conditions, outside the structure of a research cohort or
clinical trial, we used New York City (NYC) surveillance
data to explore current CD4 testing patterns among virolog-
ically and immunologically stable HIV-infected patients in
NYC, from 2007 through 2013. We also sought to determine
whether some patients could undergo less frequent CD4
testing without detriment to their clinical care.
METHODS
Study Design and Data Source
We conducted a population-based retrospective open
cohort study using the NYC HIV registry data. AIDS diagnoses
have been reportable in New York State since 1981. The New
York State law expanded AIDS case reporting on June 1, 2000
to include diagnoses of non-AIDS HIV infection as well as
laboratory tests of CD4 counts less than 500 cells per cubic
millimeter and detectable viral loads (VLs), and on June 1,
2005 to include all CD4 and VL values. The NYC HIV registry
contains all NYC HIV cases and is continuously updated with
newly confirmed diagnoses and laboratory results and vital
status on new and existing case records. As of June 30, 2014,
NYC HIV registry contained a cumulative total of over 230,000
cases and more than 8 million laboratory tests. The analysis
used surveillance data and was a public health practice activity,
not human subject research. Thus, it was exempt from
institutional review board approval.
HIV-infected patients aged $13 years were considered
“stable” if they met both of the following 2 conditions for an
entire calendar year and included for follow-up beginning on
January 1 of the next year: (1) stable viral suppression, defined
as having at least 1 VL test, with all measurements ,400
copies per milliliter and (2) stable immune status, defined as
having at least 1 CD4 test, with all measurements $200 cells
per cubic millimeter. As a full year of VL and CD4 data are
needed to determine the eligibility of each patient, and as the
year 2006 was the first full year of comprehensive HIV-related
laboratory reporting in New York State, January 1, 2007 was
the earliest date a patient could enter the cohort and be included
in the analysis. Each subsequent year, eligible patients not
previously included entered the cohort on January 1. Patients
were followed through December 31, 2013, and censored at
first VL $400 copies per milliliter or the very last CD4/VL.
Patients who exited the cohort because of a failure (CD4 count
below 200 cells per cubic millimeter) or being censored
(VL $400 copies per milliliter) were allowed to reenter the
cohort after they became eligible again with a stable immune
status (all CD4 counts $200 cells per cubic millimeter) and
a stable viral suppression status (all VL ,400 copies per
milliliter) for an entire calendar year.
Measurements
The primary outcome measure was the frequency of
CD4 monitoring in a year between 2007 and 2013; the
secondary outcome measure was the probability of the CD4
dropping ,200 cells per cubic millimeter. The initial CD4
count on January 1 (when the patient entered the cohort) was
calculated based on the values of the last CD4 count in the
previous year and the first CD4 count on or after January 1 of
the cohort entry year, assuming a linear change by time
between the 2 tests.
Statistical Analysis
For the primary outcome measure analysis, we first
described the frequency of CD4 monitoring by year, using
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mean (SD), median [interquartile range (IQR)], and frequency
categories. We then limited our analysis to the 2013
population to examine the frequency of CD4 monitoring in
subgroups, by sex, race/ethnicity, age, transmission risk, and
year of diagnosis. Data from 2013 were used because they
were the most recent year for which complete data were
available due to the slight lag in laboratory reporting.
For the secondary outcome measure analysis, the
Kaplan–Meier product limit method was used to estimate
the cumulative proportion of patients maintaining CD4 count
$200 cells per cubic millimeter after they entered the cohort,
stratified by sex (male/female), race/ethnicity, age, trans-
mission risk, year of diagnosis, and initial CD4 count, with
log-rank tests to assess differences between groups. Patients
were censored at the date of their first VL $400 copies per
milliliter, after they entered or reentered the cohort, or last
CD4/VL test, if patients’ CD4 count never dropped to below
200 cells per cubic millimeter by the end of the analysis
period, December 31, 2013. A multivariable Cox proportional
hazard regression model with 6 independent variables (sex,
race/ethnicity, age, transmission risk, year of diagnosis, and
initial CD4 count) was used to identify factors associated with
maintaining CD4 count $200 cells per cubic millimeter and
to calculate the respective adjusted hazard ratios.
All analyses were conducted using SAS 9.2 (SAS
Institute, Cary, NC).
RESULTS
A total of 62,039 unique patients were included
in the open cohort and were added by year as follows:
21,946 (2007), 9489 (2008), 7202 (2009), 6747
(2010), 5961 (2011), 5572 (2012), and 5122 (2013)
(Table 1). The number of patients who reentered the
cohort was 13,242, assigned by year: 1765 (2009), 2680
(2010), 2900 (2011), 2893 (2012), and 3004 (2013) (data
not shown in Table 1).
Frequency of CD4 Testing Among Stable
Patients With HIV
Over the interval, the mean annual number of CD4
measurements among stable patients was between 2.7 and 2.9
and showed no significant variation by year (2007–2013)
(Table 2). In 2013, 23.5% of stable patients with HIV had 4 or
more CD4 measurements, and the annual number of CD4
measurements among stable patients was found to vary little
by sex, race/ethnicity, transmission risk, or year of diagnosis,
but the most frequent testing seemed to occur among patients
at the extremes of age: 33.3% of persons 13–17 years, and
29.6% of persons 65 and older had $4 tests per year,
compared with 25.0% of persons 18–24 years, 20.7% of
persons 25–44 years, and 24.9% of persons 45–64 years
(Table 3).
TABLE 1. Characteristics of Stable Patients With HIV (N = 62,039) Enrolled in a Retrospective Open Cohort in NYC, by Year of
Enrollment, 2007–2013
2007 2008 2009 2010 2011 2012 2013 Total
Total 21,946 9489 7202 6747 5961 5572 5122 62,039
Sex
Male 15,481 6544 4956 4820 4368 4105 3786 44,060
Female 6465 2945 2246 1927 1593 1467 1336 17,979
Race/ethnicity
Black 8870 3922 3135 2987 2605 2510 2293 26,322
Hispanic 6982 3368 2349 2155 1967 1794 1714 20,329
White 5588 2014 1546 1405 1229 1118 966 13,866
Other/unknown 506 185 172 200 160 150 149 1522
Age group, yrs
13–17 182 79 58 52 40 38 27 476
18–24 242 178 185 236 262 293 329 1725
25–44 8400 3836 2887 2781 2620 2558 2435 25,517
45–64 12,107 5014 3788 3391 2855 2473 2174 31,802
65+ 1015 382 284 287 184 210 157 2519
Transmission risk
MSM 7888 3308 2579 2613 2450 2418 2421 23,677
IDU 3527 1532 1035 840 656 558 432 8580
MSM-IDU 469 210 147 170 130 127 82 1335
Heterosexual 4463 2000 1599 1455 1274 1209 1104 13,104
Other/unknown 5599 2439 1842 1669 1451 1260 1083 15,343
Year of diagnosis
Pre-1995 6106 2372 1642 1296 906 714 582 13,618
1995–1999 6878 2462 1598 1268 892 762 573 14,433
2000–2004 8195 3420 2241 1959 1552 1215 958 19,540
2005–2012 767 1235 1721 2224 2611 2881 3009 14,448
IDU, injection drug users; MSM, men who have sex with men.
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Probability of CD4 Dropping to ,200 Cells
Per Cubic Millimeter
There were a total of 201,546 patient-years of observa-
tion in total, with a per-patient mean of 2.7 and a median of 1.9
(IQR, 0.8–4.3) patient-years. Two years after entering the
cohort, 71.6%, 93.4%, and 98.1% of those with initial CD4 cell
counts of 200–349 (N = 11,025), 350–499 (N = 16,347), and
$500 cells per cubic millimeter (N = 34,667), respectively,
maintained CD4 $200 cells per cubic millimeter (Fig. 1). It
took 1.5 years for 25% of patients with an initial CD4 of 200–
349 to experience a CD4 count ,200 cells per cubic
millimeter. And even after a median of 5 years of observation,
only 4.6% of those with an initial CD4 cell count of$500 cells
per cubic millimeter experienced a CD4 count ,200 cells per
cubic millimeter. In 2013, compared to those with initial CD4
$500 cells per cubic millimeter, those with CD4 200–349 cells
per cubic millimeter and CD4 350–499 cells per cubic
millimeter were significantly more likely to have a CD4 dip
,200 cells per cubic millimeter, controlling for sex, race/
ethnicity, age, transmission risk, and diagnosis year (Table 4).
DISCUSSION
In this large population-based, urban US cohort with
well-controlled HIV, initial CD4 at cohort entry was a strong
independent predictor of maintaining CD4 $200 cells per
cubic millimeter. Specifically, the probability of maintaining
CD4 $200 cells per cubic millimeter for at least 2 years was
96.7% among those with an initial CD4 $350 cells per cubic
millimeter. These findings support the recent shift in national
and local guidelines, which now recommend annual moni-
toring for patients with consistent viral suppression. The
findings also support the growing consensus about CD4
testing in resource-limited settings that was reflected in the
proceedings of a September, 2013 WHO expert consultation
on the future role of CD4 testing for ART monitoring.14 In
addition, these findings provide further support to the decision
to decouple CD4 testing from VL testing in stable, virolog-
ically suppressed patients and to focus exclusively on the
maintenance of virologic suppression as the sole indicator of
successful ongoing therapy. Paired with the somewhat
diminished role of CD4 cell count staging in determining
the need for ART at initial diagnosis,2–4 these findings might
signal the waning importance of CD4 testing more broadly,
although it is worth noting that the CD4 cell count,
particularly when conducted at the point of care, has a key
operational role in linkage to HIV care.16
TABLE 2. Frequency of CD4 Testing Among Stable Patients With HIV in NYC, 2007–2013
2007 2008 2009 2010 2011 2012 2013
N % N % N % N % N % N % N %
Total patients 17,207 ― 21,670 ― 25,175 ― 28,674 ― 31,174 ― 33,021 ― 38,824 ―
Total CD4 tests 46,278 ― 60,465 ― 72,070 ― 81,925 ― 84,736 ― 91,834 ― 104,972 ―
Mean (6SD) 2.7 (1.4) ― 2.8 (1.4) ― 2.9 (1.4) ― 2.9 (1.4) ― 2.7 (1.3) ― 2.8 (1.3) ― 2.7 (1.2) ―
Median (IQR) 3 (2–4) ― 3 (2–4) ― 3 (2–4) ― 3 (2–4) ― 3 (2–4) ― 3 (2–4) ― 3 (2–3) ―
No. CD4 tests
0 1276 7.4 1327 6.1 1385 5.5 1494 5.2 1830 5.9 1444 4.4 738 1.9
1 2051 11.9 2311 10.7 2372 9.4 2801 9.8 3554 11.4 3455 10.5 5361 13.8
2 4032 23.4 4883 22.5 5563 22.1 6278 21.9 7312 23.5 8039 24.4 10,739 27.7
3 5168 30.0 6790 31.3 8165 32.4 9215 32.1 10,249 32.9 11,019 33.4 12,853 33.1
$4 4680 27.2 6359 29.3 7690 30.6 8886 31.0 8229 26.4 9064 27.5 9133 23.5
TABLE 3. Frequency of CD4 Testing Among Stable Patients
With HIV (N = 38,824) in NYC, 2013
Total
0 or 1 CD4
Test




N (%) N (%) N (%)
Total 38,824 6099 (15.7) 23,592 (60.8) 9133 (23.5)
Sex
Male 27,806 4541 (16.3) 16,802 (60.4) 6463 (23.2)
Female 11,018 1558 (14.1) 6790 (61.6) 2670 (24.2)
Race/ethnicity
Black 15,731 2304 (14.6) 9606 (61.1) 3821 (24.3)
Hispanic 12,709 1584 (12.5) 7819 (61.5) 3306 (26.0)
White 9272 2049 (22.1) 5457 (58.9) 1766 (19.0)
Other/unknown 1112 162 (14.6) 710 (63.8) 240 (21.6)
Age group, yrs
13–17 192 15 (7.8) 113 (58.9) 64 (33.3)
18–24 1011 155 (15.3) 603 (59.6) 253 (25.0)
25–44 15,215 2600 (17.1) 9462 (62.2) 3153 (20.7)
45–64 20,691 3092 (14.9) 12,443 (60.1) 5156 (24.9)
65+ 1715 237 (13.8) 971 (56.6) 507 (29.6)
Transmission risk
MSM 16,050 2887 (18.0) 9659 (60.2) 3504 (21.8)
IDU 4216 531 (12.6) 2457 (58.3) 1228 (29.1)
MSM-IDU 726 76 (10.5) 433 (59.6) 217 (29.9)
Heterosexual 8278 1128 (13.6) 5217 (63.0) 1933 (23.4)
Other/unknown 9554 1477 (15.5) 5826 (61.0) 2251 (23.6)
Year of diagnosis
Pre-1995 7670 1092 (14.2) 4509 (58.8) 2069 (27.0)
1995–1999 8769 1380 (15.7) 5291 (60.3) 2098 (23.9)
2000–2004 11,991 1949 (16.3) 7386 (61.6) 2656 (22.1)
2005–2012 10,394 1678 (16.1) 6406 (61.6) 2310 (22.2)
Initial CD4 count
200–349 5124 857 (16.7) 3082 (60.1) 1185 (23.1)
350–499 9802 1415 (14.4) 6037 (61.6) 2350 (24.0)
500+ 5124 857 (16.7) 14,473 (60.6) 5598 (23.4)
IDU, injection drug users; MSM, men who have sex with men.
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Over the 2007–2013 interval, in the absence of any
clinical recommendations to the contrary, clinicians main-
tained a practice of obtaining almost 3 CD4 measurements per
year. In fact, 85% of virologically and immunologically stable
patients had testing at least twice yearly. Compared with the
frequency of VL testing in 2013 [mean (SD), 2.8 (1.2);
median (IQR), 3 (2–4)], the frequency of CD4 measure-
ments implies that many NYC clinicians continued to
include CD4 testing on the panel of tests every time that
a patient had blood drawn for other testing during this
interval despite previous evidence of virologic suppression.
Whether practice patterns will change going forward will
depend on a number of factors, including provider aware-
ness and understanding of the new recommendations and the
ability of clinical practice sites to adjust operationally. A
related factor will be the willingness of patients (and
providers) to forgo this additional “check” of their immune
status. Physician factors can likely be overcome with
operational changes, which might include modifying stan-
dard laboratory order templates used in HIV primary care
settings (to drop CD4 cell count testing); patient factors can
likely be managed through thoughtful conversations by
providers and other forms of patient education. Ultimately,
removal of the CD4 cell count from expected monitoring
may diminish patient and provider anxiety that previously
arose from natural fluctuations in CD4 cell count values.13
The finding that CD4 testing varied little by year of
diagnosis was initially surprising. Anecdotally, patients
diagnosed earlier in the epidemic were characterized as
being more wedded to following (and perhaps even request-
ing) this indicator of their health and immune status, even in
the face of virologic suppression. But ultimately, those
diagnosed before 1995 were only slightly more likely than
persons diagnosed in more recent years to have had$4 CD4
tests in 2013 (27.0% vs. 22.2% for all other year of
diagnosis combined).
In contrast with at least 1 previous analysis,11 we
allowed patients to reenter the cohort after they became
eligible again (with a stable immune status and a stable viral
suppression status for an entire calendar year); we felt that
this decision would allow our study population to more
accurately reflect the true population of clinically stable
patients. Importantly, however, when we repeated our
analysis using only one data point for each patient, we found
essentially the same results: 2 years after entering the cohort,
72.2%, 93.4%, and 98.3% (vs. 71.6%, 93.4%, and 98.1%) of
those with initial CD4 cell counts of 200–349, 350–499, and
$500 cells per cubic millimeter, respectively, maintained
CD4 $200 cells per cubic millimeter. Also, in contrast with
at least 1 other previous analysis,15 we used a single CD4
drop to ,200 as an endpoint. However, in an additional
analysis (not shown) using a “confirmed” CD4 drop ,200
(ie, 2 CD4 cell counts ,200), the findings are even more
robust: 2 years after entering the cohort, 94.9%, 99.2%, and
99.8% of those with initial CD4 cell counts of 200–349, 350–
499, and $500 cells per cubic millimeter, respectively,
maintained CD4 $200 cells per cubic millimeter.
This analysis has several important limitations. First,
the use of surveillance data for the analytic cohort is limited
by the fact that only CD4 measurements obtained in the
jurisdiction could be considered. This could lead to an
underestimate of both the CD4 testing frequency and the
probability of the CD4 dipping to ,200 cells per cubic
TABLE 4. Factors Associated With CD4 Count Dropping to
Below 200 Cells Per Cubic Millimeter Among Stable Patients
With HIV (N = 38,824) in NYC, 2013
adjHR 95% CI P
Sex
Male 1.00 ― ―
Female 1.07 1.01 to 1.15 0.03
Race/ethnicity
Black 1.00 ― ―
Hispanic 1.24 1.15 to 1.33 ,0.001
White 1.20 1.12 to 1.29 ,0.001
Other/unknown 0.76 0.61 to 0.94 0.01
Age group, yrs
13–17 1.00 ― ―
18–24 0.59 0.38 to 0.90 0.01
25–44 0.66 0.46 to 0.94 0.02
45–64 0.84 0.59 to 1.19 0.32
65+ 1.18 0.82 to 1.69 0.37
Transmission risk
MSM 1.00 ― ―
IDU 1.90 1.76 to 2.04 ,0.001
MSM-IDU 1.64 1.42 to 1.91 ,0.001
Heterosexual 1.15 1.06 to 1.26 ,0.01
Other/unknown 1.23 1.14 to 1.32 ,0.001
Year of diagnosis
Pre-1995 1.65 1.51 to 1.80 ,0.001
1995–1999 1.43 1.31 to 1.56 ,0.001
2000–2004 1.28 1.17 to 1.39 ,0.001
2005–2012 1.00 ― ―
Initial CD4 count, cells/mm3
200–349 12.88 12.04 to 13.78 ,0.001
350–499 3.19 2.96 to 3.45 ,0.001
500+ 1.00 ― ―
adjHR, adjusted hazard ratio; IDU, injection drug users; MSM, men who have sex
with men.
FIGURE 1. Proportion of stable patients with HIV maintaining
CD4$200 cells per cubic millimeter in NYC, by initial CD4 cell
count.
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millimeter. However, as the number of patients receiving CD4
monitoring in more than one jurisdiction is likely to be small,
and as there is no reason to suspect more frequent dips in CD4
counts generated by the same cohort during testing events
outside of NYC, this “incomplete” CD4 reporting may
have minimal impact on our analysis. Furthermore, other
covariates, such as factors that might drive CD4 trajectories
or measurement frequency (eg, concomitant chemotherapy, any
other immunosuppressive medication, ART use) are not avail-
able without chart review. However, our finding that the
probability of the CD4 dipping to ,200 cells per cubic
millimeter was still quite small even with the inclusion of such
patients only underscores the minimal likelihood that stable
patients without any of these comorbidities will experience
a dip to CD4 ,200 cells per cubic millimeter. Another major
limitation is that the definition of stable viral suppression (VL
,400 copies per milliliter) exceeds that used currently for
NYC HIV surveillance analyses (VL #200 copies per
milliliter) and also exceeds that used for years by clinicians.
It is a vestige of an early era of less precision in laboratory
monitoring. However, if a more strict definition (VL #200
copies per milliliter) had been used, we would have expected to
observe an even higher probability that stable patients were
able to maintain their CD4 count $200 cells per cubic
millimeter, thereby proving even stronger evidence that stable
patients need less frequent CD4 monitoring.
Limitations aside, the implications of these findings are
quite clear. As 2 sets of national guidelines already recommend,
limited CD4 monitoring is appropriate for patients with CD4
$350 cells per cubic millimeter who are stably virologically
suppressed. Additional testing in this context is unlikely to
require clinical action (eg, initiation of prophylaxis for OIs). And
continued CD4 monitoring for virologically suppressed patients
whose CD4 counts have been consistently .500 cells per cubic
millimeter for at least 2 years may be considered optional. The
fact that our analysis uses population-based data derived from
a large surveillance data set (rather than data from a clinical trial
or program-based cohort) further underscores the relevance and
importance of the findings.
As others have reported, these findings also have
important fiscal implications.6,13,15 At the New York State
Medicaid rate of US $64.93 for a CD4 test (2013), for stable
patients with CD4 $350 cells per cubic millimeter, NYC in
2013 would have saved ;US $1.5 million if CD4 moni-
toring had been limited to twice yearly, and ;US $3.7
million if CD4 monitoring were limited to once yearly. Cost
savings will be even greater in coming years as the number
of persons living with HIV in NYC and the US increases,
and new guidelines recommending ART for all HIV-
infected patients regardless of CD4 count are imple-
mented.2,17,18 Curbing these unnecessary expenses can help
reduce the overall cost of HIV care at a time when there is
uncertainty in funding. Moreover, forgoing laboratory
testing of questionable necessity provides important albeit
less tangible benefits such as prevention of provider and
patient anxieties surrounding test results of uncertain
significance. Future analyses are planned to study the
impact of various new sets of clinical guidelines released
in 2014 that also advise less frequent monitoring of stable
patients and to ensure that these initial findings are robust as
patients are followed over a greater number of years of
virologic suppression.
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